Biophytis Reinforces Leadership Teams with Three Senior Appointments Fullscreen Mode
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study Fullscreen Mode
Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021.
Biophytis announces new convertible bonds financing up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million
Interview of Stanislas Veillet on Boursier.com
Biophytis Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis.
Results of the Combined General Meeting on May 10, 2021
Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders
Biophytis receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD
Biophytis – Convening of Another Combined General Meeting at a Later Date